IN2014DN08964A - - Google Patents

Info

Publication number
IN2014DN08964A
IN2014DN08964A IN8964DEN2014A IN2014DN08964A IN 2014DN08964 A IN2014DN08964 A IN 2014DN08964A IN 8964DEN2014 A IN8964DEN2014 A IN 8964DEN2014A IN 2014DN08964 A IN2014DN08964 A IN 2014DN08964A
Authority
IN
India
Prior art keywords
cells
diseases
specific regulatory
antigen specific
suppressing
Prior art date
Application number
Other languages
English (en)
Inventor
Remy Jean Marie Saint
Original Assignee
Imcyse Sa
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa, Univ Leuven Kath filed Critical Imcyse Sa
Publication of IN2014DN08964A publication Critical patent/IN2014DN08964A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN8964DEN2014 2012-04-30 2013-04-29 IN2014DN08964A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640537P 2012-04-30 2012-04-30
PCT/EP2013/058835 WO2013164289A1 (en) 2012-04-30 2013-04-29 Methods for induction of antigen-specific regulatory t cells

Publications (1)

Publication Number Publication Date
IN2014DN08964A true IN2014DN08964A (cs) 2015-05-22

Family

ID=48483027

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8964DEN2014 IN2014DN08964A (cs) 2012-04-30 2013-04-29

Country Status (13)

Country Link
US (1) US20150125880A1 (cs)
EP (1) EP2844741A1 (cs)
JP (1) JP2015518376A (cs)
KR (1) KR20150028225A (cs)
CN (1) CN104411818A (cs)
AU (1) AU2013255888A1 (cs)
BR (1) BR112014026606A2 (cs)
CA (1) CA2871541A1 (cs)
HK (1) HK1206786A1 (cs)
IN (1) IN2014DN08964A (cs)
RU (1) RU2014148172A (cs)
WO (1) WO2013164289A1 (cs)
ZA (1) ZA201407298B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540255B1 (es) * 2013-11-19 2016-05-12 Tomás SEGURA MARTÍN Método de aislamiento de cuerpos apoptóticos
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
KR20240015731A (ko) * 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
CA3094886A1 (en) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
WO2019209073A1 (ko) * 2018-04-27 2019-10-31 사회복지법인 삼성생명공익재단 세포의 자성 비드 부착을 통한 자성 기반 바이오 패닝 방법
CN114341346B (zh) * 2019-09-03 2025-04-04 恩立夫克治疗研发公司 用于治疗骨关节炎的治疗性凋亡细胞
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5750600B2 (ja) * 2006-08-11 2015-07-22 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ 免疫原性ペプチドおよび免疫障害におけるその使用
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
EP2249855B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation

Also Published As

Publication number Publication date
CA2871541A1 (en) 2013-11-07
HK1206786A1 (en) 2016-01-15
EP2844741A1 (en) 2015-03-11
JP2015518376A (ja) 2015-07-02
US20150125880A1 (en) 2015-05-07
RU2014148172A (ru) 2016-06-20
AU2013255888A1 (en) 2014-10-23
CN104411818A (zh) 2015-03-11
WO2013164289A1 (en) 2013-11-07
KR20150028225A (ko) 2015-03-13
ZA201407298B (en) 2016-02-24
BR112014026606A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX2013010793A (es) Metodo y composiciones para inmunoterapia celular.
IN2014DN08964A (cs)
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2019014960A (es) Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
MX2022010807A (es) Productos de celulas t modificadas de genes de composicion definida.
PH12017500803A1 (en) Anti-pd-1 antibodies
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
WO2015154012A8 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
SG178991A1 (en) Anti-gitr antibodies
MY185016A (en) Progenitor cells of mesodermal lineage
EA201391601A1 (ru) Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических т-лимфоцитов
MX382772B (es) Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
EP3122181A4 (en) Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
IN2014CN03892A (cs)
JO3593B1 (ar) مركبات تعمل على زيادة الخلايا الجذعية المكونة للدم
MX388754B (es) Terapéuticos dirigidos a la glucosa.
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
IN2015DN00263A (cs)
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
MY192295A (en) Peptides and methods for the treatment of diabetes
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+
WO2014133728A3 (en) Hhla2 as a novel inhibitor of human immune system and uses thereof
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
PH12012502233A1 (en) Methods and compositions for inhibition of treg cells